Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Marvel Biosciences Corp

MRVL.V ✓ COMPLIANTFree checks used up today ☆ Track — members

TSX · Healthcare · Biotechnology & Medical Research ·

Canada Micro Cap Analyst: N/A

Last Close

$0.09

▲ +0.00%

Market Cap $6.33M · Vol 4.13K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$6.33M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

58.33

Momentum

Beta

0.37

vs Market

52W High

$0.18

52.31% below

52W Low

$0.07

27.44% above

Volume

4.13K

Avg 80.66K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

74.05%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Marvel Biosciences Corp (MRVL.V) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does MRVL.V pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-4.00%

+0.00%

-20.00%

-27.27%

YTD

-11.11%

-45.45%

+67.42%

-53.85%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-1,596,499.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-540.68% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	73.80M

Technical Indicators

50-Day SMA	$0.10
200-Day SMA	$0.11
RSI (14)	58.33
Beta	0.37
52-Week High	$0.18
52-Week Low	$0.07

Volume Today	4.13K
Avg Daily Volume (30D)	80.66K
Relative Volume	0.05x
Volatility (10D)	122.01
Volatility (30D)	111.28
Free Float	74.05%

Analyst Consensus

N/A

Current Price $0.09

Mean Target N/A

52W Low$0.07 52W High$0.18

Current

Target

$0.07 $0.18

Current Analyst target

· 0 analysts

Identifiers

ExchangeTSX

FIGIBBG00MXMTCB6

ISINCA57384M1077

CountryCanada

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +0.62% ONC BeOne Medicines AG -2.45% 068270.KS Celltrion, Inc. -1.09% MEDP Medpace Holdings, Inc. -0.59% CRL Charles River Laboratories International, Inc. -5.81%

Company Profile

Marvel Biosciences Corp. is a Canada-based pre-clinical-stage pharmaceutical development biotechnology company. The Company develops new synthetic chemical derivatives of the original approved drug for the new disease indication. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs that inhibit the A2a adenosine receptor with application to neurological diseases (depression and anxiety, Alzheimer's, attention deficit hyperactivity disorder (ADHD)), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. The Company's lead compound, MB-204, is a fluorinated derivative of Istradefylline. The Company is engaged in developing MB-204 for diseases other than Parkinson's disease, specifically depression, Alzheimer’s Disease and liver fibrosis due to non-alcoholic steatohepatitis (NASH). Its wholly owned subsidiary is Marvel Biotechnology Inc.